

Emerging patterns in clonal haematopoiesis

Jose-Mario Capo-Chichi,¹ Phillip Michaels,² Rosemarie Tremblay-Le May,² Sagi Abelson,^{3,4} Robert Paul Hasserjian,⁵ Daniel Xia^{6,2}

¹Department of Molecular Genetics, Toronto General Hospital, Toronto, Ontario, Canada

²Department of Pathology, University Health Network, Toronto, Ontario, Canada

³Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

⁴Ontario Institute for Cancer Research, Toronto, Ontario, Canada

⁵Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

Correspondence to

Dr Daniel Xia, Pathology, University Health Network, Toronto, ON M5G 2C4, Canada; daniel.xia@uhn.ca

J-MC-C, PM and RT-LM contributed equally.

Received 20 March 2019
Accepted 21 March 2019
Published Online First
4 June 2019

ABSTRACT

Clonal haematopoiesis (CH) is defined by the presence of acquired mutations and/or cytogenetic abnormalities in haematopoietic cells. By definition, these premalignant clones do not meet criteria for haematopoietic neoplasms listed in the Revised Fourth Edition of the WHO classification. CH is fairly common in elderly individuals and is associated with higher risks for haematological cancers, in particular myelodysplastic syndrome and acute myeloid leukaemia (AML), as well as cardiovascular events. Similar small clones have also been detected during follow-up in patients with AML in morphological remission, in individuals with aplastic anaemia, and in pre-chemotherapy blood samples from patients with other types of cancers. In each of these contexts, the presence of mutations carries different clinical implications, and sometimes demonstrates unique genetic profiles. Emerging research suggests that the number and identity of mutations, the size of the mutant clones and various other factors, including age, immune status and history of exogenous drugs/toxins, are important for disease biology and progression. This review focuses specifically on the subset of CH with gene mutations detected by sequencing, and includes discussions of nomenclature and molecular technologies that detect and quantify gene mutations.

INTRODUCTION

The concept of clonal haematopoiesis (CH) relates to the natural history of myeloid neoplasms, before the development of overt morphological and clinical features. CH is defined by the presence of acquired mutations and/or cytogenetic alterations in haematopoietic cells, in the absence of significant morphological abnormalities and often in the context of normal peripheral blood counts. By definition, these clones do not meet criteria for haematopoietic neoplasms in the current WHO classification.¹ CH is fairly common in elderly individuals and is associated with elevated risks for haematopoietic malignancies,^{2–4} in particular myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). As high-throughput sequencing becomes increasingly widespread, a working understanding of CH in different contexts can be helpful to pathologists who are increasingly likely to encounter these in practice. This short review focuses on the subset of CH with gene mutations detected by sequencing, which is often referred to as CH of indeterminate potential (CHIP) or age-related CH (ARCH) in the literature; we discuss this and other nomenclatures used to describe the phenomenon of CH, the technologies used to detect and quantify mutations, as well as more recent research. Readers interested in

CH with cytogenetic abnormalities, which is not the focus of this manuscript, may consider additional recent reviews.^{5,6}

The association between clonal leukocytes and ageing was first suggested by X-inactivation studies in women. During female embryonic development, the maternal or paternal X chromosomes are inactivated at random, which in principle, results in a roughly 50:50 pattern of X-inactivation in the cells of adults. What researchers found, however, was that these ratios in the blood leukocytes from some women were skewed and that the proportion of people with skewing increased with age.⁷ Several non-mutually exclusive explanations had been put forth to explain this age-associated skewing (AAS). One hypothesis pointed to decreasing numbers of haematopoietic stem cells in older people, suggesting that the skewing is caused by small numbers of precursor cells with genetic drift. Another hypothesis proposed that haematopoietic stem cells in some older individuals acquire gene mutations that promote proliferation and/or survival, causing mutated clones to preferentially expand over their wild-type counterparts. Support for the clonality hypothesis came in 2012, when Busque *et al*⁸ found somatic mutations in *TET2*, a gene important for the pathogenesis of myeloid neoplasms, in the blood samples from a subset of elderly women with AAS.

Following this, in 2014, three research groups separately published analyses of exome sequencing performed on blood samples from large cohorts of individuals without known haematological malignancies.^{2–4} These investigators found recurrent mutations in genes known to be associated with myeloid neoplasms, most frequently *DNMT3A*, *TET2* and *ASXL1*, in small but not insignificant percentages of people. As with AAS, the percentage of people with peripheral blood mutations increased with age: CH was found to be uncommon in those younger than 50 years,³ but was present in 10% or more of those older than 70 years.² In contrast to the mutational profiles of MDS and AML,^{9–13} CH demonstrated the following: (1) fewer total numbers of mutations, (2) a more restricted set of involved genes (ie, mainly a few epigenetic regulators) and (3) lower mutant variant allele fractions (VAFs, usually <10%), consistent with smaller and genetically simpler clones. There was about a 10-fold elevated risk for myeloid malignancies among those with CH in comparison to those without CH^{2,3}; however, the overall rate of progression to overt leukaemia was relatively low, estimated at 0.5%–1.0% per person per year, similar to the progression rates of monoclonal gammopathy



© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Capo-Chichi J-M, Michaels P, Tremblay-Le May R, *et al*. *J Clin Pathol* 2019;**72**:453–459.

Table 1 Common terms encountered in the literature

Term	Definition
Clonal haematopoiesis of indeterminate potential	Evidence of clonality, not meeting WHO criteria for a haematological neoplasm or another clonal disorder
Age-related clonal haematopoiesis	Clonality in haematopoietic cells identified in elderly individuals
Clonal cytopenia of undetermined significance	Persistent unexplained cytopenia(s) with evidence of clonality, not meeting WHO criteria for a haematological neoplasm
Idiopathic cytopenia of undetermined significance	Persistent unexplained cytopenia(s) without significant dysplasia or evidence of clonality
Idiopathic dysplasia of undetermined significance	Presence of significant dysplasia, without cytopenias or evidence of clonality

In the most recent WHO classification¹ for MDS, cytopenia is generally defined as haemoglobin <100 g/L, platelet count <100×10⁹/L, or neutrophil count <1.8×10⁹/L. However, milder cytopenias are considered acceptable for MDS and recent consensus guidelines by Valent *et al*²⁷ recommend that thresholds for CH should be defined in relation to institutional reference ranges. A persistent cytopenia must be at least 4 months in duration. Dysplasia is defined as at least 10% morphological dysplasia in the myeloid, erythroid, or megakaryocytic lineages. Evidence of clonality refers to the presence of genes mutations (≥2% VAF) or cytogenetic abnormalities associated with haematopoietic neoplasms.

CH, clonal haematopoiesis; MDS, myelodysplastic syndrome; VAF, variant allele fraction.

of undetermined significance (MGUS)¹⁴ and monoclonal B-cell lymphocytosis (MBL).¹⁵ Individuals with CH also experienced shorter survival during follow-up.^{2,3} Interestingly, this finding was not explained by deaths from haematopoietic cancers, as there were relatively few such events in the cohorts. Relevant to this observation, Jaiswal *et al*² showed that CH was also associated with an increased risk for cardiovascular events. More recent research argue that this association is likely causal^{16,17} (see below, for further discussion of the relationship between CH and cardiovascular disease [CVD]).

NOMENCLATURE FOR CH

Before proceeding further, it is important to point out there have been a variety of terms used to describe CH in the literature. In




Figure 1 Venn diagram illustrating the relationship between clonal haematopoiesis and related entities with respect to morphological dysplasia, cytopenia(s) and clonality. Please note that the Venn diagram is not to scale; for example, CHIP is much more common than MDS. For this figure, cytopenia and dysplasia are as defined in table 1; clonality refers to the presence of mutations and/or cytogenetic abnormalities, whether or not these are detected by testing. The diagnostic criteria for specific MDS entities are detailed in the WHO classification.¹ In one commonly cited reference, CCUS is considered to be a form of CHIP¹⁸; however, others have proposed that CCUS and CHIP should be distinguished.²⁷ The 'other' category includes non-clonal causes of cytopenia and abnormal morphology (eg, copper deficiency). CCUS, clonal cytopenia of undetermined significance; CHIP, clonal haematopoiesis of indeterminate potential; ICUS, idiopathic cytopenia of undetermined significance; IDUS, idiopathic dysplasia of undetermined significance; MDS, myelodysplastic syndrome.

comparison to entities in the WHO classification, this nomenclature is not as well established, and different terms are often used interchangeably. Two frequently encountered acronyms are CHIP and ARCH. Table 1 lists definitions for these and other related terms.

According to one reference,¹⁸ CHIP must fulfil two requirements: (1) the presence of acquired mutation(s) in genes associated with haematopoietic neoplasms, provisionally at a VAF ≥2% and (2) overall findings not meeting criteria for any WHO-defined entity, including MGUS and MBL, as well as other diseases that can have small haematopoietic clones, such as paroxysmal nocturnal haemoglobinuria. As defined, CHIP typically refers to elderly individuals with mutations who do not have cytopenias. The subset of cases with both mutations and cytopenia(s) may be more specifically designated as 'clonal cytopenia of undetermined significance' (CCUS) (figure 1), which are associated with genetically more complex clones and higher risk for progression to myeloid malignancies compared to cases of CHIP without cytopenia.^{19–21} 'Idiopathic cytopenia of undetermined significance' (ICUS, or more precisely non-clonal ICUS) is defined by unexplained cytopenia(s) in the absence of evidence of clonality or defining features of a WHO entity (figure 1), and this appears to have a lower risk for malignant progression than CCUS.²⁰

Another commonly encountered four-letter acronym, ARCH, largely overlaps with CHIP, and emphasises the relationship between CH and ageing.⁵ However, it is important to note that CH is not limited to older individuals and can occur in other contexts; recent studies have identified small clones in patients with aplastic anaemia (AA)²² and those being treated with chemotherapy.^{23–26} In these settings, the presence of CH appears to be shaped by selective pressures (autoimmune and cytotoxic, respectively), and can occur in younger people.

Figure 1 illustrates the nomenclature for CH in relations to morphological abnormalities(s), cytopenia(s) and clonality. Notably, CH is not an official entity in the Revised Fourth Edition of the WHO classification¹; it is distinguished from myeloid neoplasms by the absence of significant morphological findings (dysplasia or increased blasts) and/or cytopenia(s). Since the spectrum of mutations in CH overlaps with MDS and other myeloid neoplasms, gene mutations cannot be used at this time to reliably distinguish CH from MDS or other WHO entities. One consequence of this is that most gene mutations identified by high-throughput sequencing are not used as diagnostic biomarkers in the current WHO classification,¹ although these mutations may contribute relevant prognostic and predictive information. Nevertheless, recent research and guidelines raise the possibility that the pattern of gene mutations can be helpful in the diagnosis of MDS cases with borderline morphologic

Table 2 Molecular technologies used for the assessment of CH: a comparison of approaches

	Droplet digital PCR	Whole exome next generation sequencing (NGS)	Targeted NGS	Targeted NGS with molecular barcodes	Targeted NGS with molecular inversion probes (MIPs)
Principle	Partitioning of single DNA templates into micro-droplets, followed by end-point PCRs and enumeration of fluorescent droplets	High-throughput sequencing of all coding regions from the human genome (ie, the exome)	High-throughput sequencing of selected exons and genes recurrently mutated in cancers (eg, myeloid neoplasms)	Short molecular barcode sequences are attached to DNA fragments during library construction; otherwise, similar to targeted NGS	MIPs, which carry tag sequences, are used to capture targeted DNA regions via hybridization prior to sequencing
Comprehensiveness of testing; potential clinical/research uses	Low; suitable for small numbers of "hotspot" mutations	High; suitable for defining reference mutational landscapes of cancers	Moderate to high, depending on the panel; suitable for clinical testing or biomarker research once the recurrently mutated genes are known		
Barcoding/error correction	N/A	No	Yes		
Typical limit of detection	0.01%–0.1%	As low as 2%–3%			≤0.1%
Amount of input DNA required	Low	Medium to high			Medium
Samples per run	Variable, depending on number of tests and platform	Relatively few samples	More samples than WES		
Other consideration/comments	Absolute quantification of VAFs	VAFs are approximate			► Near absolute quantification of VAFs ► Additional cost of molecular barcodes in comparison to targeted NGS without barcodes
				► Near absolute quantification of VAFs ► Near absolute quantification of VAFs	

PCR-based testing, while analytically sensitive and inexpensive, is often restricted to the assessment of small numbers of 'hotspot' mutations. By contrast, sequencing in general allows for the more comprehensive evaluation of larger complements of mutations. Among sequencing approaches, WES, while comprehensive, is comparatively limited in terms of depths of coverage (limited analytical sensitivity) and the numbers of samples that can be sequenced at one time. The incorporation of molecular barcodes and similar tag sequences in some workflows allows for the distinction between low-level mutations and sequencing artefacts, thereby greatly improving the analytical sensitivity for low-level mutations.

MIPs, molecular inversion probes; NGS, next-generation sequencing; VAFs, variant allele fractions; WES, whole exome sequencing.

features.^{20 27} It is possible that our existing ideas and nomenclature regarding CH and myeloid neoplasms will evolve as new research and frameworks emerge.

SEQUENCING TECHNOLOGIES USED TO DETECT CH

Different molecular approaches used to characterise CH are summarised in [table 2](#). In this section, we focus on platforms used to detect point mutations and small insertions, duplications, and deletions. Although larger genomic alterations (eg, a deletion demonstrated by conventional karyotype) are also important for the biology of myeloid neoplasms,^{28 29} cytogenetic testing will not be covered in this review.

The mutational profiles of CH were defined by comprehensive whole exome sequencing (WES, ie, the sequencing of all coding regions in the human genome).²⁻⁴ These exploratory studies provided proof of clonality and helped to establish the reference mutational landscape. Although comprehensive, the disadvantages of WES include high costs per sample and complexity; in addition, WES can be insensitive and may miss low-level driver mutations (eg, <2% VAF) that are clinically important (see below).

In clinical laboratories at the present time, the most common approach available for the evaluation of CH and myeloid neoplasms is targeted next-generation sequencing (NGS). These NGS panels focus on genes and exons recurrently mutated in haematopoietic neoplasms; since the regions sequenced are much smaller than the entire exome, greater sequencing depths at targeted loci can be achieved, potentially improving analytical sensitivity and lowering the limit of detection.

To further improve sensitivity for low-level mutations (eg, for the detection of minimal residual disease (MRD) and other settings) some sequencing technologies additionally incorporate

molecular barcodes or similar tag sequences that uniquely label individual DNA templates.^{23 25 26 30-34} With these unique labels, investigators were better equipped to discriminate true low-level mutations from low-level technical artefacts that arise during the course of sequencing. NGS with molecular barcodes or molecular inversion probes (MIPs, which have analogous tag sequences) can detect and precisely quantify small clones with VAFs ≤0.1%, a level of sensitivity comparable to quantitative and droplet digital PCRs³⁴⁻³⁷ ([table 2](#)). In comparison to PCR-based methods, NGS with molecular barcodes or MIPs are more comprehensive, and are not limited to the assessment small numbers of 'hotspot' mutations, which is a major disadvantage of PCR ([table 2](#)).

Not surprisingly, the degree of analytical sensitivity can impact results. For example, several studies^{31 34} using more sensitive techniques have shown that the incidences of CH may be much higher than that detected in earlier studies using WES. Recent research has also linked low-level mutations (<0.1% VAFs) in pre-treatment blood samples from patients with non-myeloid cancers with the subsequent development of therapy-related myeloid neoplasms (t-MNs) following chemotherapy with or without autologous stem cell transplantation^{23 25 26}; notably, many of these low-level mutations are below the limit of detection for WES. We will return to the topic of selecting an appropriate method to detect mutations in the section 'Should we test for CH at this time?'

PROGRESSION FROM CHIP TO MDS TO AML

Sequencing studies of CHIP²⁻⁴ and myeloid neoplasms, including MDS⁹⁻¹¹ and AML,^{12 13} have identified recurrent mutations in genes involved in diverse biological processes, including DNA methylation, histone modification, RNA splicing, tumour




Figure 2 Morphology, mutations and the evolution of a myeloid neoplasm in a hypothetical individual. Each row is a snapshot of the clonal architecture at a specific time. Haematopoietic cells at each time point are represented by circles. The dots within the circles represent mutations. Black circles without dots are normal haematopoietic cells. The blue dots are early events in the pathogenesis of myeloid neoplasms (eg, a mutation in *DNMT3A*, *TET2* or *ASXL1*). At this stage, there is no overt dysplasia in mutated cells (black). As the clone expands, it may acquire additional mutations (yellow/gold dot, eg, a mutation in *SF3B1*) associated with morphological abnormalities (yellow cells), ineffective haematopoiesis and cytopenias, enabling pathologists to formally diagnose MDS. The acquisition of late genetic events (green and red dots, eg, including a mutation involving *FLT3*) is associated with rapid progression of disease and increased blasts (red cells), leading to AML. Following chemotherapy for AML, residual mutant clones may be detected by sequencing. Please note that only a small percentage of individuals with CHIP will develop a WHO-defined myeloid neoplasm. AML, acute myeloid leukaemia; CHIP, clonal haematopoiesis of indeterminate potential; MDS, myelodysplastic syndrome.

suppression (eg, via *TP53*), cell signalling, the cohesin complex and transcriptional regulation.

A comparison of the mutational profiles of CHIP and myeloid neoplasms at different stages of evolution reveal interesting patterns. For example, mutations in CHIP tend to occur in genes coding for specific epigenetic regulators.²⁻⁴ Epigenetics refers to modifications to DNA and histones (proteins that help 'package' DNA) that impact gene expression. *DNMT3A* (coding for DNA methyltransferase 3A) and *TET2* (which affects DNA demethylation) are involved in DNA methylation; mutations in these genes change global methylation patterns, and alter the expression of many other genes, including those important for myeloid function and differentiation.²⁸ *ASXL1* regulates histone modifications, which also impacts gene transcription.²⁸ CHIP in older individuals without cytopenias most often involve a single mutation in one of these genes, at a low VAF (usually <10%).²⁻⁴

By comparison, haematopoietic clones detected in the blood of patients with cytopenia(s) (ie, CCUS) often affect multiple genes at higher VAFs (often >10%).¹⁹⁻²¹ The probability of finding mutations in patients with cytopenias is also significantly higher than that in the general elderly population. The spectrum of mutations and VAFs in CCUS more closely overlaps with MDS, and includes mutations in spliceosome genes, with the exception of *SF3B1*.¹⁹⁻²¹ Depending on the specific pattern of mutations, CCUS may demonstrate a much higher risk for progression²⁰ to overt myeloid malignancies than CHIP without cytopenia.

In comparison to CCUS, MDS has more frequent mutations in *SF3B1*,⁹⁻¹¹ which are closely associated with the presence of ring sideroblasts in all WHO myeloid neoplasm subtypes. In MDS and myelodysplastic/myeloproliferative neoplasms, the presence

of additional cooperating mutations in genes involved in cell signalling (including *NRAS* and *FLT3*), transcription (including *RUNX1* and *NPM1*), as well as in *IDH1* and *IDH2*, is associated with increased blasts and/or rapid progression to AML.²⁸

Accordingly, one plausible model is that mutations involving *DNMT3A*, *TET2* and *ASXL1* (ie, those common in CHIP) are early events in the pathogenesis of myeloid neoplasms, while the acquisition of mutations in genes coding for transcription factors or those involved in signalling are later events, heralding impending transformation to acute leukaemia (figure 2). With respect to this hypothesis, some have recently proposed that the subset of CH with gene mutations that show greater specificity for true myeloid neoplasms could be referred to as 'CH of oncogenic potential',³⁸ which is to be distinguished from typical CHIP in the elderly. This pattern of early and late events raises the possibility that CH can be genetically risk stratified. Indeed, initial publications had shown that individuals with larger and more complex CHIP clones have a higher risk of subsequent myeloid neoplasms, although there was insufficient statistical power at that time to link mutations in specific genes to risk for AML.³⁹

More recently in 2018, two groups^{40 41} explored the association between antecedent mutations in CH and the risk for AML in greater detail. Banked blood samples from sizeable cohorts several years before the development of AML (cases), as well as samples from similar individuals who did not develop AML (controls), were sequenced. The researchers found that CH was more frequent in cases than controls. Consistent with earlier studies, more mutations and higher VAFs were associated with higher risk. In addition, mutations in certain genes, including

those encoding spliceosome components, *TP53* and *IDH1/2* displayed a particularly high risk for progression, sometimes even at low VAFs. Remarkably, Abelson *et al*⁴⁰ additionally developed a machine-learning algorithm that used routine complete blood count parameters (eg, leukocyte counts and red blood cell distribution width) from the preceding year to predict risk of AML. Although the data are very promising, screening of the general elderly population (in particular, using large NGS panels covering all the putative driver mutations in AML associated genes) may be premature at this time, as the low overall incidence of AMLs could lead to lower positive predictive values, in comparison to performance in case-control studies.⁴⁰

CH IN OTHER CONTEXTS

Small haematopoietic clones observed in situations not directly related to ageing carry different clinical implications, and often different genetic profiles. The present section also includes a discussion of the relationship between CH and CVD.

Molecular MRD and AML relapse

Emerging data indicate that identifying persistent CH after treatment for AML has important implications for patient outcome. As an example of MRD monitoring for the subset of AML with mutated *NPM1*, Ivey *et al*³⁵ developed a reverse transcriptase PCR assay to detect low-level mutations in patients in morphological remission. The authors found that the presence of residual *NPM1* mutations was associated with significantly higher risk for relapse and shorter survival.

Jongen-Lavrenic *et al*⁴² studied a broader array of residual mutations in patients with AML in morphological remission via targeted NGS. In this study, while mutations isolated to the so-called 'DTA' genes (ie, *DNMT3A*, *TET2* and *ASXL1*, which are relatively frequent in elderly individuals with CHIP) appeared to confer no obvious adverse outcomes upon follow-up, non-DTA mutations (which are found in biologically more advanced clones, eg, see figure 2) were associated with significantly higher rates of relapse and shorter survival.

Aplastic anaemia

Yoshizato *et al*²² identified CH in approximately 50% of AA patients from two large cohorts. The unique genetic profile in AA suggests that clones with specific mutations were selected for in the setting of autoimmunity. On follow-up, clones with mutations in *BCOR*, *BCORL1*, and *PIGA* were more likely to remain stable in size and respond to immunosuppression, and these patients had longer survival. Conversely, clones with mutations in *DNMT3A* and *ASXL1* were more likely to expand over time, and were associated with inferior outcomes.

Therapy-related myeloid neoplasms

Recent research has also modified our understanding of the pathogenesis of t-MNs. While the traditional hypothesis had been that chemotherapy itself causes mutations in haematopoietic stem cells, Wong *et al*²⁶ identified very low-level mutations in *TP53* (a gene recurrently mutated in t-MNs) using NGS with molecular barcoding in the blood samples of patients prior to the development of t-MNs, and in some cases, prior to the patients receiving any chemotherapy. Interestingly, leukocytes carrying heterozygous *TP53* mutations preferentially expanded following exposure to cytotoxic injury in mouse models. Since the overall mutation rates are similar between cases of t-AML and de novo AML, the authors argued that rather than causing mutations, the primary role of chemotherapy in the pathogenesis of t-MNs

is to select for pre-existing low-level chemo-resistant clones, including those carrying mutated *TP53*.

This model is supported by subsequent studies. Takahashi *et al*²⁵ and Gillis *et al*²³ showed that in patients who received chemotherapy, pre-existing low-level mutations, including those involving *TP53*, were more frequent in patients who eventually developed t-MNs (cases), than in those who did not. In many cases, the small clones were detected using NGS with molecular barcoding prior to chemotherapy. In a similar study, Gibson *et al*²⁴ showed that CH was common following chemotherapy for lymphomas given prior to autologous stem cell transplantation (ASCT). The presence of CH in this setting, mostly characterised by mutations in *TP53* and *PPM1D*, was associated with elevated risks for t-MNs and cardiovascular events, and shorter survival, following ASCT. Since mutations may be detectable prior to therapeutic interventions (ie, chemotherapy and ASCT), these could serve as useful predictive biomarkers, enabling clinicians to identify patients at higher risk for developing t-MNs.

The relationship between CH and CVD

In 2014, Jaiswal *et al*² found in their exome sequencing study that CH was associated with higher risks for coronary artery disease and stroke. Since there were very few leukaemia-related deaths in their cohort, the authors proposed that the increase in mortality they observed may be in large part attributable to cardiovascular causes. More recently, Fuster *et al*¹⁷ and Jaiswal *et al*¹⁶ both investigated for a causal relationship between CH and CVD, using low-density lipoprotein-deficient (atherosclerosis prone) mice with reconstituted marrows carrying homozygous and heterozygous mutation in *TET2*. These animals showed expansion of *TET2*-mutated clones and larger aortic root plaques in comparison to controls on high-fat diets. In Fuster *et al*,¹⁷ *TET2*-mutated macrophages showed increased interleukin-1 beta production via the NLRP3 inflammasome; interestingly, an NLRP3 inhibitor reduced the size of plaques in *TET2*-deficient mice. Jaiswal *et al*¹⁶ similarly demonstrated via expression profiling the overexpression of several chemokines and cytokines in *TET2*-mutated macrophages, and additionally linked mutations in *DNMT3A*, *TET2*, *ASXL1* and *JAK2* to CVD in four independent cohorts. The overall findings from these studies support the idea that higher cardiovascular risk in CH is caused at least in part by mutant macrophages that drive aberrant inflammation, leading to accelerated atherosclerosis.

SHOULD WE TEST FOR CH AT THIS TIME?

Based on existing studies, potential indications for testing for the presence of mutations in haematopoietic cells include the following: risk stratification in patients with cytopenias, patients with cancer who are about to receive chemotherapy with or without autologous stem cell transplantation, prospective bone marrow donors (for the risk of donor-derived leukaemias in recipients),⁴³ patients with AML in morphological remission and individuals at risk for CVD. However, there are many considerations that have not been fully worked out. Importantly, while drugs targeting specific mutations are under investigation,⁴⁴ it is unclear how best to manage CH in most settings. In other words, there is actually little data at this time concerning potentially beneficial clinical interventions that patients could expect from sequencing their blood samples. From a molecular testing perspective, there is also no consensus regarding how best to test for CH. NGS gene panels will likely require updates as additional biologically important mutations are discovered. In addition, the choice of specific technology platforms will likely vary

Take home messages

- Clonal haematopoiesis (CH) is defined by the presence of somatic mutations and/or cytogenetic abnormalities in haematopoietic cells.
- These clones do not show morphological abnormalities under the microscope, and occur most frequently in elderly individuals with normal blood counts, distinguishing them from myeloid neoplasms in the WHO classification.
- CH is associated with the development of haematological malignancies and cardiovascular disease.
- The specific clinical implications of CH in different contexts are dependent on the identity and number of mutations, the size of the mutant clones and several other factors (eg, autoimmunity and exposure to chemotherapy).
- As we learn more, the nomenclature used to describe CH, as well as the molecular technologies used, will likely evolve.

across laboratories and require consideration of DNA target size, DNA input amount, the expected volume of cases, the numbers of samples that could be run at one time, requirements for analytical sensitivity and variant quantification, and other factors (table 2). For example, higher sensitivity may be preferable for the detection of MRD and small pre-existing *TP53* clones in patients who are about to undergo chemotherapy; however, a highly sensitive assay may also detect very small incidental clones in elderly individuals with unexplained cytopenias that may be inconsequential.

Irrespective of this, as the use of sequencing technologies becomes more widespread in clinical diagnosis, a working understanding of CH can be helpful to haematopathologists in practice. For example, sequencing performed on a peripheral blood sample from a patient with cytopenias may reveal CCUS. Testing performed on a bone marrow aspirate from a patient with AML in morphological remission may show mutations that confer a higher risk for relapse. At institutions and laboratories with large pan-cancer NGS panels, somatic mutations in genes associated with myeloid neoplasms (eg, *DNMT3A* or *JAK2*) may be detected, incidentally, during sequencing of solid tumours.^{45–48} Such a result can be difficult to interpret without further work-up. Conceivably, the mutations could have originated from the solid tumours or background infiltrating leukocytes, but without sequencing of a concurrent blood or bone marrow sample, this distinction can be difficult. If the mutation is shown to originate from the leukocytes, a thorough haematological work-up, including possibly a bone marrow biopsy, may be required to separate incidental CH from a concurrent myeloid neoplasm.

CONCLUDING COMMENTS

In summary, emerging research suggests that the biological significance of CH depends on the number and identity of mutations, the sizes of mutant clones, as well as, critically, other factors, including patient age, immune status, exogenous drugs/toxins, and perhaps even traditional CVD risk measures. As we learn more about CH, the methods we use to detect mutations will likely evolve in parallel, as clinical needs change. Over time, new methods, ideas, frameworks, and nomenclatures will likely emerge, enabling us to better communicate the molecular underpinnings of myeloid neoplasms.

Handling editor Runjan Chetty.

Contributors JC, PM, RTL and DX contributed to the conception, drafting and revising of the manuscript. SA and RPH provided critical feedback and revised the manuscript. All authors approve the version of the manuscript for submission.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

REFERENCES

- 1 Swerdlow SH, Campo E, Harris NL, *et al.* *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Revised 4th. WHO Press: Lyon; 2017.
- 2 Jaiswal S, Fontanillas P, Flannick J, *et al.* Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med Overseas Ed* 2014;371:2488–98.
- 3 Genovese G, Köhler AK, Handsaker RE, *et al.* Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med* 2014;371:2477–87.
- 4 Xie M, Lu C, Wang J, *et al.* Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med* 2014;20:1472–8.
- 5 Shlush LI. Age-related clonal hematopoiesis. *Blood* 2018;131:496–504.
- 6 Tang G, Medeiros LJ, Wang SA. How I investigate clonal cytogenetic abnormalities of undetermined significance. *Int J Lab Hematol* 2018;40:385–91.
- 7 Busque L, Mio R, Mattioli J, *et al.* Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. *Blood* 1996;88:59–65.
- 8 Busque L, Patel JP, Figueroa ME, *et al.* Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. *Nat Genet* 2012;44:1179–81.
- 9 Bejar R, Stevenson K, Abdel-Wahab O, *et al.* Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med* 2011;364:2496–506.
- 10 Haferlach T, Nagata Y, Grossmann V, *et al.* Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia* 2014;28:241–7.
- 11 Papaemmanuil E, Gerstung M, Malcovati L, *et al.* Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood* 2013;122:3616–27.
- 12 Ley TJ, Miller C, Ding L, *et al.* Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* 2013;368:2059–74.
- 13 Lindsley RC, Mar BG, Mazzola E, *et al.* Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood* 2015;125:1367–76.
- 14 Kyle RA, Therneau TM, Rajkumar SV, *et al.* A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med* 2002;346:564–9.
- 15 Rawstron AC, Bennett FL, O'Connor SJM, *et al.* Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. *N Engl J Med* 2008;359:575–83.
- 16 Jaiswal S, Natarajan P, Silver AJ, *et al.* Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med* 2017;377:111–21.
- 17 Fuster JJ, MacLauchlan S, Zuriaga MA, *et al.* Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science* 2017;355:842–7.
- 18 Steensma DP, Bejar R, Jaiswal S, *et al.* Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood* 2015;126:9–16.
- 19 Kwok B, Hall JM, Witte JS, *et al.* MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. *Blood* 2015;126:2355–61.
- 20 Malcovati L, Galli A, Travaglio E, *et al.* Clinical significance of somatic mutation in unexplained blood cytopenia. *Blood* 2017;129.
- 21 Cargo CA, Rowbotham N, Evans PA, *et al.* Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. *Blood* 2015;126:2362–5.
- 22 Yoshizato T, Dumitriu B, Hosokawa K, *et al.* Somatic mutations and clonal hematopoiesis in aplastic anemia. *N Engl J Med* 2015;373:35–47.
- 23 Gillis NK, Ball M, Zhang Q, *et al.* Clonal haematopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. *Lancet Oncol* 2017;18:112–21.
- 24 Gibson CJ, Lindsley RC, Tchekmedyan V, *et al.* Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. *J Clin Oncol* 2017;35:1598–605.
- 25 Takahashi K, Wang F, Kantarjian H, *et al.* Preleukaemic clonal haematopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. *Lancet Oncol* 2017;18:100–11.
- 26 Wong TN, Ramsingh G, Young AL, *et al.* Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. *Nature* 2015;518:552–5.
- 27 Valent P, Orazi A, Steensma DP, *et al.* Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. *Oncotarget* 2017;8:73483–500.
- 28 Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. *Nat Rev Cancer* 2017;17:5–19.
- 29 Loh P-R, Genovese G, Handsaker RE, *et al.* Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. *Nature* 2018;559:350–5.

- 30 Young AL, Wong TN, Hughes AEO, *et al.* Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing. *Leukemia* 2015;29:1608–11.
- 31 Acuna-Hidalgo R, Sengul H, Steehouwer M, *et al.* Ultra-sensitive sequencing identifies high prevalence of clonal Hematopoiesis-Associated mutations throughout adult life. *Am J Hum Genet* 2017;101:50–64.
- 32 Waalkes A, Penewit K, Wood BL, *et al.* Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes. *Haematologica* 2017;102:1549–57.
- 33 Cantsilieris S, Stessman HA, Shendure J, *et al.* *Genotyping*. New York, NY: Springer, 2017.
- 34 Young AL, Challen GA, Birmann BM, *et al.* Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. *Nat Commun* 2016;7.
- 35 Ivey A, Hills RK, Simpson MA, *et al.* Assessment of minimal residual disease in standard-risk AML. *N Engl J Med* 2016;374:422–33.
- 36 Parkin B, Londoño-Joshi A, Kang Q, *et al.* Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. *J Clin Invest* 2017;127:3484–95.
- 37 Link-Lenczowska D, Pallisgaard N, Cordua S, *et al.* A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in pMDS negative MPNs. *Ann Hematol* 2018;97:2299–308.
- 38 Valent P, Kern W, Hoermann G, *et al.* Clonal hematopoiesis with oncogenic potential (CHOP): separation from CHIP and roads to AML. *Int J Mol Sci* 2019;20. doi:10.3390/ijms20030789. [Epub ahead of print: 12 Feb 2019].
- 39 Sellar RS, Jaiswal S, Ebert BL. Predicting progression to AML. *Nat Med* 2018;24:904–6.
- 40 Abelson S, Collord G, Ng SWK, *et al.* Prediction of acute myeloid leukaemia risk in healthy individuals. *Nature* 2018;559:400–4.
- 41 Desai P, Mencia-Trinchant N, Savenkov O, *et al.* Somatic mutations precede acute myeloid leukemia years before diagnosis. *Nat Med* 2018;24:1015–23.
- 42 Jongen-Lavrencic M, Grob T, Hanekamp D, *et al.* Molecular minimal residual disease in acute myeloid leukemia. *N Engl J Med* 2018;378:1189–99.
- 43 Abelson S, Wang JCY. Age-related clonal hematopoiesis: implications for hematopoietic stem cell transplantation. *Curr Opin Hematol* 2018;25:441–5.
- 44 Gibson CJ, Steensma DP. New insights from studies of clonal hematopoiesis. *Clin Cancer Res* 2018;24:4633–42.
- 45 Severson EA, Riedlinger GM, Connelly CF, *et al.* Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. *Blood* 2018;131:2501–5.
- 46 Coombs CC, Gillis NK, Tan X, *et al.* Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. *Clin Cancer Res* 2018;24:5918–24.
- 47 Ptashkin RN, Mandelker DL, Coombs CC, *et al.* Prevalence of clonal hematopoiesis mutations in Tumor-Only clinical genomic profiling of solid tumors. *JAMA Oncol* 2018;4:1589–93.
- 48 Riedlinger G, Hadigol M, Khabanian H, *et al.* Association of Jak2-V617F mutations detected by solid tumor sequencing with coexistent myeloproliferative neoplasms. *JAMA Oncol* 2019. doi:10.1001/jamaoncol.2018.6286. [Epub ahead of print: 03 Jan 2019].